Trial Profile
A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SERENADE
- Sponsors Actelion Pharmaceuticals
- 23 Mar 2021 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 12 Jan 2021 Planned End Date changed from 9 Dec 2020 to 12 Mar 2021.